Centaurus Financial’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Centaurus Financial’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$160K	Buy	1,254 +128	+11%	+$16K	0.01%	888
2025 Q4	$137K	Buy	1,126 +2	+0.2%	+$229	0.01%	926
2025 Q3	$113K	Buy	+1,124	New	+$101K	0.01%	982
2024 Q4	–	Sell	-4,215	Closed	-$416K	–	934
2024 Q3	$416K	Buy	+4,215	New	+$414K	0.03%	452
2024 Q2	–	Sell	-19,864	Closed	-$1.89M	–	850
2024 Q1	$1.89M	Buy	19,864 +6,456	+48%	+$599K	0.13%	154
2023 Q4	$1.2M	Buy	+13,408	New	+$996K	0.09%	209
2023 Q3	–	Sell	-1,880	Closed	-$156K	–	809
2023 Q2	$156K	Buy	+1,880	New	+$157K	0.01%	625
2023 Q1	–	Sell	-3,704	Closed	-$307K	–	946
2022 Q4	$307K	Sell	3,704 -380	-9%	-$30.8K	0.03%	481
2022 Q3	$324K	Sell	4,084 -20,198	-83%	-$1.7M	0.03%	461
2022 Q2	$1.8M	Buy	+24,282	New	+$1.82M	0.18%	150
2021 Q4	–	Sell	-31,241	Closed	-$3.93M	–	985
2021 Q3	$3.93M	Buy	31,241 +20,561	+193%	+$2.65M	0.33%	70
2021 Q2	$1.45M	Buy	10,680 +1,299	+14%	+$171K	0.12%	202
2021 Q1	$1.27M	Buy	9,381 +8,130	+650%	+$1.22M	0.13%	199
2020 Q4	$176K	Buy	+1,251	New	+$160K	0.02%	586
2020 Q3	–	Sell	-1,605	Closed	-$180K	–	708
2020 Q2	$180K	Buy	+1,605	New	+$158K	0.03%	453
2020 Q1	–	Sell	-9,509	Closed	-$904K	–	664
2019 Q4	$904K	Buy	+9,509	New	+$823K	0.13%	192
2018 Q3	–	Sell	-4,354	Closed	-$414K	–	2060
2018 Q2	$414K	Sell	4,354 -10,224	-70%	-$940K	0.06%	345
2018 Q1	$1.28M	Buy	14,578 +581	+4%	+$53K	0.3%	85
2017 Q4	$1.19M	Buy	+13,997	New	+$1.17M	0.31%	88

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Centaurus Financial's XBI Position: Q1 2026 in Review

Centaurus Financial increased its State Street SPDR S&P Biotech ETF (XBI) stake by 11% in Q1 2026, buying an estimated $16K and bringing the position to 1,254 shares worth $160K. The position accounts for 0.01% of the portfolio, ranked #888.

Centaurus Financial first reported a position in XBI in Q4 2017 and has held it in 19 quarters since. The position peaked at $3.93M in Q3 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Centaurus Financial held 1,254 shares of State Street SPDR S&P Biotech ETF worth $160K as of Q1 2026.
Centaurus Financial bought 128 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $16K.
State Street SPDR S&P Biotech ETF made up 0.01% of Centaurus Financial's portfolio in Q1 2026, its #888 holding.
Centaurus Financial first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 19 quarters since.
Centaurus Financial's State Street SPDR S&P Biotech ETF position peaked at $3.93M in Q3 2021.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.